左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要がありそうです。 https://t.co/FFqLKVINUM # HFpEF # β-blocker https://t.co/GYVjNoePbx
Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Nov 2021 – Oct 2025Where it's discussed
-
X / Twitter209 posts
-
Facebook5 posts
-
YouTube3 videos
-
News3 articles
-
Blogs2 articles
AI synopsis
What people are saying
The overall tone suggests strong support and curiosity about the study's implications, exemplified by phrases like
Most discussions acknowledge that withdrawing beta-blockers may improve functional capacity in HFpEF, showing general support for the study's findings.
The discussions demonstrate high interest, with many references to the latest research, ongoing debates, and potential changes in clinical practice.
Posts reference specific studies, trial outcomes, and implications for treatment, indicating deep engagement with the research.
While some highlight the potential for practice changes, others emphasize ongoing research and debate, so the perceived impact is moderate but significant.
Abstract in brief
- This study investigated how stopping blockers affects exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF) and chronotropic incompetence, showing that withdrawing blockers significantly improved peak oxygen consumption.
- The trial was a multicenter, randomized crossover designed to compare the effects of continued treatment versus withdrawal, revealing that patients' maximal functional capacity increased after stopping blockers.
- Overall, the findings suggest that discontinuing blockers may enhance exercise ability in HFpEF patients with chronotropic issues, indicating a need to reconsider the routine use of blockers in this population.
Top posts
Most liked on X and BlueskyEditors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and possibly even hinder some patients: Do you agree? Let us know in the comments below! https://t.co/j7LtgoLoEf #JACC #CardioTwitter #HeartFailure #SportsCardio https://t.co/2ksxZcgSjC
“β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction | Journal of the American College of Cardiology https://t.co/vqDiy3nITK
El trabajo y la constancia = éxito
Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction”. Un orgullo recogerlo en representación de @yulnunezvill @EloyDomnguez6 @JuliaSellerm https://t.co/iiPbF1YhtC
The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3kgrA @BerrischR @Ch_Stumpf @AG32_DGK @AG14_DGK @ChristianRost10 @drjohnm https://t.co/z1EmGIZ6Ye
All mentions
Impact of Beta-Blocker Withdrawal on Exercise Capacity in HFpEF Patients
This study investigated how stopping blockers affects exercise capacity in patients with heart failure with preserved ejection fraction and chronotropic incompetence, showing that withdrawing blockers significantly…
Blood Flow Imaging in Cardiology: Coronary CTA Reduces 5-Year Heart Attack Risk
A multicenter trial with 4146 patients found that adding coronary CT angiography to standard care reduced the 5-year risk of death from coronary heart disease or nonfatal myocardial infarction, improving patient…
Innovative Approaches in Managing Heart Failure with Preserved Ejection Fraction
This week's cardiology update covers new insights into diastolic dysfunction, HFpEF, MRI scanning, and treatments such as accelerated pacing and blocker withdrawal, emphasizing personalized strategies to improve patient…
「変時不全(chronotropic incompetence)」っていう概念を今更ながら初めて知った! β遮断→適切に脈拍数が増えない→運動機能の低下 ってことがあるらしい。 HFpEF患者へのβはエビデンス乏しいのは有名だけど、患者さんによっては害になりうるかもしれない…!
RT @JuliaSellerm:
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
@abdelhamed012 Many pts with HFpEF have inability to increase stroke volume with exercise so depend on ⬆️HR to augment CO. And BB withdrawal trial showed benefit in HFpEF (https://t.co/2DJkLyAvRj). NEAT-HFpEF nitrate trial in HFpEF: no benefit to possible harm: https://t.co/umqZqmWOm6
@AAmin_cardio Carvedilol is a great anti-HTN drug given its BB, alpha-block, and CCB properties (https://t.co/jVFgbrthVl), it's like a polypill. I used to use if all the time. COHERE registry supported its use in HFpEF. But recent BB withdrawal trial showed benefit: https://t.co/2DJkLyAvRj
RT @CardioCaribeMx: #Competencia #cronotropica Multicéntrico clínico cruzado Px FEVI conservada 2 sem con retiro (o no) de beta-bloqueador…
#Competencia #cronotropica Multicéntrico clínico cruzado Px FEVI conservada 2 sem con retiro (o no) de beta-bloqueador Después de 2 sem la intervención opuesta Promedio 72 â, 60% ♀️ Pico #VO2 12.4 mlkgmin Al retiro ⬆️ VO2 a 14.3 mlkgmin DOI: 10.1016/j.jacc.2021.08.073 https://t.co/QEu84GECe3
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
@shivadas29 @SABOURETCardio @NeeChe @lipo_fan https://t.co/ZiOohITnjj
RT @nrajag: @drjohnm @gcfmd @JavedButler1 @MaggieInfeld Yes, more recently there has been discussion that beta blockers are overused in HFp…
what is the long term effect of chronic RV pacing in patients with AF and HFpEF? time for a large outcomes-based RCT of beta blockers in HFpEF? https://t.co/ChlgK7eu6i
@drjohnm @gcfmd @JavedButler1 @MaggieInfeld Yes, more recently there has been discussion that beta blockers are overused in HFpEF. See this paper: Palau P, Seller J, Domínguez E, et al. Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. https://t.co/KWABdnkHC8
@drjohnm @gcfmd @JavedButler1 @MaggieInfeld I saw this a while ago... May be related https://t.co/LdLQaRxGku
@drjohnm @JAMACardio @lusty63 It’s possible that reason is in unfavourable effect of slowing HR in HFpEF (especially with BBs - negative lusitropy, DD progression, chronotropic incompetence). https://t.co/dtf2FS46qW and https://t.co/8ElE6MwZjw. But interesting that frequency of BB use in HFpEF is still ~80%…
@GaneshMuthappan @MarkusMeyerMD @DNSilvermanMD @MaggieInfeld @JAMACardio I do. Very few HFpEF pts with absolute indications for BB use. And some suggestions of harm: https://t.co/i0oaHwJcrZ https://t.co/9ETlEljyyz
RT @ValleAlfonso: El trabajo y la constancia = éxito
RT @ValleAlfonso: El trabajo y la constancia = éxito
RT @ValleAlfonso: El trabajo y la constancia = éxito
RT @ValleAlfonso: El trabajo y la constancia = éxito
RT @ValleAlfonso: El trabajo y la constancia = éxito
El trabajo y la constancia = éxito
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction https://t.co/I9D7e708Gt
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
RT @JSE_JAYEF: 左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要…
左室駆出率の保持された心不全(HFpEF)では、evidenceがないにも関わらず、β-blockerが頻用されています。運動時の心拍応答不全を有するHFpEF患者のβ-blocker中止は運動耐容能を改善すると報告され、同薬の使用を見つめ直す必要がありそうです。 https://t.co/FFqLKVINUM # HFpEF # β-blocker https://t.co/GYVjNoePbx
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
RT @PatriciaPalau1: Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functio…
Gracias a la fundación @MutualMedica por el reconocimiento a nuestro trabajo “Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction”. Un orgullo recogerlo en representación de @yulnunezvill @EloyDomnguez6 @JuliaSellerm https://t.co/iiPbF1YhtC
@kidney_boy https://t.co/2R4hJBSC5R
RT @CardioRoland: @gcfmd @HFSA @JavedButler1 @paheidenreich @JCardFail @texhern In contrast, betablockers in HFPEF decrease QoL…another rea…
RT @CardioRoland: @gcfmd @HFSA @JavedButler1 @paheidenreich @JCardFail @texhern In contrast, betablockers in HFPEF decrease QoL…another rea…
@gcfmd @HFSA @JavedButler1 @paheidenreich @JCardFail @texhern In contrast, betablockers in HFPEF decrease QoL…another reason to avoid them in HFPEF https://t.co/Msa7Y6kKZ1
RT @CardioRoland: @mvaduganathan @gcfmd @naderjo In fact: withdrawing them improves QoL. Improvement of QoL is an endpoint we, physicians t…
@mvaduganathan @gcfmd @naderjo In fact: withdrawing them improves QoL. Improvement of QoL is an endpoint we, physicians tend to underestimate when compared to mortality or rehospitalisation in our prescription process… https://t.co/d4ynxJsISQ
Thank you Dr. Nunez for presenting your important work to the @nyulangone Advanced Heart Failure Journal Club helping us eloquently understand the negative impact of beta blocker use in patients with HFPEF https://t.co/Av3EJ7lllq
I have lost track of how many patients with dyspnea/fatigue feel better after discontinuing unnecessary beta blocker treatment https://t.co/bRZRBz64fk #cardiotwitter
RT @ValleAlfonso: Thanks to @PatriciaPalau1 @JuliaSellerm @SantasEnrique @yulnunezvill @rdelaespriella @gema_minana @IcUnidad @HospitaldeDe…
RT @ValleAlfonso: Thanks to @PatriciaPalau1 @JuliaSellerm @SantasEnrique @yulnunezvill @rdelaespriella @gema_minana @IcUnidad @HospitaldeDe…
RT @MGol_MD: @SeguraCardio @JCardFail @robmentz @dranulala @j_alvarezgarcia @paomorejon @HFpEF @gcfmd @ShelleyZieroth @IcyfaSemi @SIAC_card…
@SeguraCardio @JCardFail @robmentz @dranulala @j_alvarezgarcia @paomorejon @HFpEF @gcfmd @ShelleyZieroth @IcyfaSemi @SIAC_cardio Great overview! Maybe as therapeutic add-ons, titrating down beta-blockers (if no other reasons of use such as Afib etc) and SGLT2-Inhibitor utilization. Sources: 1) https://t.co/TaOsQmEdWT 2) https://t.co/NEMZHPFoWc
@DavidLBrownMD @purviparwani Why not taper the beta blocker? Because the EF is still 50% and not 60%? I think that alone will improve QOL enough that he would agree to keep the rest of the drugs https://t.co/4PVkMZjkBT
RT @JuliaSellerm: 4️⃣ PRESERVE-HR
RT @almucastro01: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction Enhorabuena (aga…
RT @JuliaSellerm: 4️⃣ PRESERVE-HR
4️⃣ PRESERVE-HR
Beta bloqueantes en pacientes con FEVIp e insuficiencia cronotropica @jaccjournals https://t.co/Ljvc5C5QbD
Physiology makes sense.. No atrial kick, diastole doesn't help, less diastole = improved symptoms. Take the BB in HFpEF? Probably. #PRESERVE-HR https://t.co/Y5eg6zmwT9 https://t.co/8lX9FRM4iA
RT @HanCardiomd: PRESERVE-HR β-blocker withdrawal improved maximal functional capacity in patients with #HFpEF and chronotropic incompete…
@CardioIAN #CardioTwitter https://t.co/oqXDvmrs06
RT @JACCJournals: Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and…
RT @JACCJournals: Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and…
RT @JACCJournals: Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and…
RT @JACCJournals: Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and…
RT @JACCJournals: Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and…
RT @JACCJournals: Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and…
RT @JACCJournals: Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and…
RT @JACCJournals: Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and…
RT @JACCJournals: Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and…
In patients with #HFpEF & chronotropic incompetence, β-blocker withdrawal resulted in short-term improvement in peak Vo2 @JACCJournals https://t.co/r6WkyNPFDV
RT @JACCJournals: Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and…
RT @JACCJournals: Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and…
RT @GermanECediel: Retirar para mejorar — estudio aleatorizado que demuestra que retirar betabloqueantes en HFpEF mejora el consumo de oxíg…
Editors’ Insights: Is it time for us to re-evaluate beta blocker use in #HFpEF? New research suggests it may not help and possibly even hinder some patients: Do you agree? Let us know in the comments below! https://t.co/j7LtgoLoEf #JACC #CardioTwitter #HeartFailure #SportsCardio https://t.co/2ksxZcgSjC
RT @GermanECediel: Retirar para mejorar — estudio aleatorizado que demuestra que retirar betabloqueantes en HFpEF mejora el consumo de oxíg…
RT @GermanECediel: Retirar para mejorar — estudio aleatorizado que demuestra que retirar betabloqueantes en HFpEF mejora el consumo de oxíg…
RT @GermanECediel: Retirar para mejorar — estudio aleatorizado que demuestra que retirar betabloqueantes en HFpEF mejora el consumo de oxíg…
RT @GermanECediel: Retirar para mejorar — estudio aleatorizado que demuestra que retirar betabloqueantes en HFpEF mejora el consumo de oxíg…
RT @GermanECediel: Retirar para mejorar — estudio aleatorizado que demuestra que retirar betabloqueantes en HFpEF mejora el consumo de oxíg…
RT @SeguraCardio:
Retirar para mejorar — estudio aleatorizado que demuestra que retirar betabloqueantes en HFpEF mejora el consumo de oxígeno. ¿Aplica para todos los pacientes? Excelente campo de investigación @yulnunezvill https://t.co/0zh1ZXptrf https://t.co/AnG3nM7suH
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
【クロスオーバー試験】NYHA分類II-IIIでβ遮断薬による治療歴、変時性不全がある安定したHFpEF患者でのβ遮断薬の中止は、Peak Vo2およびPeak Vo2%を改善させた。 #ペ読 https://t.co/sbjOAmmHjm
RT @almucastro01: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction Enhorabuena (aga…
RT @HanCardiomd: PRESERVE-HR β-blocker withdrawal improved maximal functional capacity in patients with #HFpEF and chronotropic incompete…
RT @HanCardiomd: PRESERVE-HR β-blocker withdrawal improved maximal functional capacity in patients with #HFpEF and chronotropic incompete…
RT @HanCardiomd: PRESERVE-HR β-blocker withdrawal improved maximal functional capacity in patients with #HFpEF and chronotropic incompete…
RT @HanCardiomd: PRESERVE-HR β-blocker withdrawal improved maximal functional capacity in patients with #HFpEF and chronotropic incompete…
RT @HanCardiomd: PRESERVE-HR β-blocker withdrawal improved maximal functional capacity in patients with #HFpEF and chronotropic incompete…
RT @HanCardiomd: PRESERVE-HR β-blocker withdrawal improved maximal functional capacity in patients with #HFpEF and chronotropic incompete…
RT @HanCardiomd: PRESERVE-HR β-blocker withdrawal improved maximal functional capacity in patients with #HFpEF and chronotropic incompete…
RT @HanCardiomd: PRESERVE-HR β-blocker withdrawal improved maximal functional capacity in patients with #HFpEF and chronotropic incompete…
RT @drdquesada: El siempre difícil tratamiento de la insuficiencia cardíaca con fracción preservada. Medicina precisión. ⬇️⬇️ Beta bloq me…
RT @drdquesada: El siempre difícil tratamiento de la insuficiencia cardíaca con fracción preservada. Medicina precisión. ⬇️⬇️ Beta bloq me…
RT @HanCardiomd: PRESERVE-HR β-blocker withdrawal improved maximal functional capacity in patients with #HFpEF and chronotropic incompete…
RT @drdquesada: El siempre difícil tratamiento de la insuficiencia cardíaca con fracción preservada. Medicina precisión. ⬇️⬇️ Beta bloq me…
RT @HanCardiomd: PRESERVE-HR β-blocker withdrawal improved maximal functional capacity in patients with #HFpEF and chronotropic incompete…
RT @SeguraCardio:
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
Today's top #cardiology headline comes from @JACCJournals. #HeartFailure #cardiotwitter https://t.co/clvpk4yp68
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @SeguraCardio:
RT @SeguraCardio:
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @SeguraCardio:
RT @SeguraCardio:
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @SeguraCardio:
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction | Journal of the American College of Cardiology https://t.co/XnJcB9yjo0
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @SeguraCardio:
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @SeguraCardio:
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @almucastro01: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction Enhorabuena (aga…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
RT @almucastro01: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction Enhorabuena (aga…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @AndrewJSauer: “β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart…
“β-blocker use in HFpEF deserves profound re-evaluation” Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction | Journal of the American College of Cardiology https://t.co/vqDiy3nITK
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @SeguraCardio:
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @SeguraCardio:
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @SeguraCardio:
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @JuliaSellerm: Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Preserve-HR trial…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
RT @OAB1967: The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3k…
The wrong drug for a complex disease? ß-Blocker withdrawal improves functional exercise capacity in HFpEF https://t.co/cLQhu3kgrA @BerrischR @Ch_Stumpf @AG32_DGK @AG14_DGK @ChristianRost10 @drjohnm https://t.co/z1EmGIZ6Ye
お腎
こ